CN101052709B - 装载热激黑素瘤细胞体的树突细胞 - Google Patents

装载热激黑素瘤细胞体的树突细胞 Download PDF

Info

Publication number
CN101052709B
CN101052709B CN2005800364774A CN200580036477A CN101052709B CN 101052709 B CN101052709 B CN 101052709B CN 2005800364774 A CN2005800364774 A CN 2005800364774A CN 200580036477 A CN200580036477 A CN 200580036477A CN 101052709 B CN101052709 B CN 101052709B
Authority
CN
China
Prior art keywords
cells
cell
cancer cells
antigen
melanoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800364774A
Other languages
English (en)
Chinese (zh)
Other versions
CN101052709A (zh
Inventor
A·K·帕卢卡
J·邦舍罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor Research Institute
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of CN101052709A publication Critical patent/CN101052709A/zh
Application granted granted Critical
Publication of CN101052709B publication Critical patent/CN101052709B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4262—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2005800364774A 2004-10-25 2005-10-25 装载热激黑素瘤细胞体的树突细胞 Expired - Fee Related CN101052709B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62195704P 2004-10-25 2004-10-25
US60/621,957 2004-10-25
PCT/US2005/038360 WO2006047515A2 (en) 2004-10-25 2005-10-25 Dendritic cells loaded with heat shocked melanoma cell bodies

Publications (2)

Publication Number Publication Date
CN101052709A CN101052709A (zh) 2007-10-10
CN101052709B true CN101052709B (zh) 2012-06-27

Family

ID=36228381

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800364774A Expired - Fee Related CN101052709B (zh) 2004-10-25 2005-10-25 装载热激黑素瘤细胞体的树突细胞

Country Status (5)

Country Link
US (5) US20060140983A1 (enExample)
EP (1) EP1814981A4 (enExample)
JP (2) JP5623004B2 (enExample)
CN (1) CN101052709B (enExample)
WO (1) WO2006047515A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CN101511384A (zh) * 2006-06-30 2009-08-19 贝勒研究院 采用GM-CSF和α干扰素制成的并装载热处理的且杀死的癌细胞的树突状细胞
CL2007002825A1 (es) * 2007-09-28 2008-05-30 Univ De Chile Oncobiomed Metodo para generar vacunas que estimulen el sistema inmune que comprende inducir celulas mononucleares de sangre periferica a que se diferencien a apc, para luego, separar dichas apc y mezclarlas con adyuvantes; extracto de celulas tumorales; y comp
AU2009251277A1 (en) * 2008-05-29 2009-12-03 Irx Therapeutics, Inc. Mechanism of action of primary cell derived biologic
CN102076354A (zh) * 2008-07-03 2011-05-25 杜克大学 用于引发免疫应答的组合物和方法
US20100215697A1 (en) * 2009-02-26 2010-08-26 Stanimir Vuk-Pavlovic Methods and materials for making and using vaccines
AU2010248761B2 (en) 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
CN107050430B (zh) 2009-12-08 2021-10-15 伊尔克斯治疗有限公司 逆转朗格汉斯细胞免疫抑制的方法
EP2543386A1 (en) 2011-07-05 2013-01-09 Sotio a.s. Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure
US20130011438A1 (en) 2011-07-05 2013-01-10 SOTIO a.s. Means And Methods For Active Cellular Immunotherapy Of Cancer By Using Tumor Cells Killed By High Hydrostatic Pressure and Dendritic Cells
SG11201401631VA (en) * 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine with gamma interferon
CN102552891A (zh) * 2011-12-27 2012-07-11 陆华 热休克凋亡脑胶质瘤负载树突状细胞肿瘤疫苗的制备方法
CA2863653A1 (en) * 2012-02-02 2013-08-08 California Stem Cell, Inc. Pluripotent germ layer origin antigen presenting cancer vaccine
US20140065173A1 (en) * 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
WO2015040230A1 (en) * 2013-09-23 2015-03-26 Koninklijke Philips N.V. Medical apparatus for treating cells with vibrations
FR3011850B1 (fr) * 2013-10-15 2018-04-06 Cfl Biotech Vaccin therapeutique contre le cancer a base de proteines de stress rendues immunogenes
US9562219B2 (en) 2013-12-27 2017-02-07 SOTIO a.s. Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer
EP3113759B1 (en) 2014-03-05 2021-05-12 Orbis Health Solutions LLC Vaccine delivery systems using yeast cell wall particles
JP6436669B2 (ja) * 2014-07-22 2018-12-12 国立大学法人福井大学 子宮肉腫転移モデル動物
US11364264B2 (en) 2016-09-09 2022-06-21 The General Hospital Corporation Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
IL268744B2 (en) * 2017-02-17 2024-08-01 Aivita Biomedical Inc Methods for increasing the immunogenicity of tumors and preparations for autologous immunotherapeutic products against cancer using tumor cells and adapted dendritic cells
WO2026076308A1 (en) * 2024-10-03 2026-04-09 Ne1 Inc. Cancer vaccine and method of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4320111A (en) * 1977-06-14 1982-03-16 American Home Products Corporation Immunologic compositions methods of preparation and use
US4393133A (en) * 1980-06-12 1983-07-12 The Wistar Institute Of Anatomy And Biology Human hepatoma derived cell line, process for preparation thereof, and uses therefor
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US6300090B1 (en) * 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
US6455493B1 (en) * 1996-09-20 2002-09-24 University Of New Mexico Methods for using heat shock proteins
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
WO2001083713A2 (en) * 2000-04-28 2001-11-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education The use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same
EP1209226A3 (en) * 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
AU2003260426A1 (en) * 2002-08-16 2004-03-11 Glycotope Gmbh Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds
AU2003285863A1 (en) * 2002-10-09 2004-05-04 Central Iowa Health System Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830464A (en) * 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ebstein et al.Cytotoxic T Cell Responses against Mesothelioma by Apoptotic Cell-pulsed Dendritic Cells.Am J Respir Crit Care Med169 12.2004,169(12),p1322-1330.
Ebstein et al.Cytotoxic T Cell Responses against Mesothelioma by Apoptotic Cell-pulsed Dendritic Cells.Am J Respir Crit Care Med169 12.2004,169(12),p1322-1330. *
Inoue et al..Heat-Induced Drug Resistance is Associated with Increased Expression of Bcl-2 in HL60.Anticancer Research19.1999,19p3989-3992. *
Todryk et al..Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity.Cancer Immunol Immunother53 4.2003,53(4),p323-330.
Todryk et al..Heated tumour cells of autologous and allogeneic origin elicit anti-tumour immunity.Cancer Immunol Immunother53 4.2003,53(4),p323-330. *

Also Published As

Publication number Publication date
WO2006047515A2 (en) 2006-05-04
JP2008517946A (ja) 2008-05-29
US20080286314A1 (en) 2008-11-20
US20130122049A1 (en) 2013-05-16
EP1814981A2 (en) 2007-08-08
JP5623004B2 (ja) 2014-11-12
JP5894891B2 (ja) 2016-03-30
US20060140983A1 (en) 2006-06-29
WO2006047515A3 (en) 2006-11-16
JP2013014603A (ja) 2013-01-24
US20080112924A1 (en) 2008-05-15
US20080112962A1 (en) 2008-05-15
EP1814981A4 (en) 2009-09-30
CN101052709A (zh) 2007-10-10

Similar Documents

Publication Publication Date Title
US20080112924A1 (en) Dendritic Cells Loaded with Heat Shocked Melanoma Cell Bodies
JP6134763B2 (ja) ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
US20220016164A1 (en) Pharmaceutical composition for use in the treatment of pancreatic cancer
Tong et al. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors
US7015205B1 (en) Melanoma vaccine and methods of making and using same
ES2375948T3 (es) Procedimiento para aumentar la presentación de clase i de ant�?genos exógenos por células dendr�?ticas humanas.
Paczesny et al. Dendritic cells as vectors for immunotherapy of cancer
EP2185686A1 (en) Dendritic cells
CN101861163A (zh) 用于治疗黑素瘤的细胞系、含有它们的组合物、制备所述组合物的方法以及治疗方法
Koido et al. Cancer vaccine by fusions of dendritic and cancer cells
US20210353674A1 (en) Pharmaceutical composition for use in the treatment of pancreatic cancer
Di Nicola et al. Dendritic cells: specialized antigen presenting cells
西岡安彦 et al. Genetic modification of dendritic cells and its application for cancer immunotherapy
US20180325948A1 (en) Tumor antigen modified dendritic cells
US20160074489A1 (en) Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturation
JP2003512335A (ja) メラノーマワクチン並びにその製造方法及び使用方法
Murugaiyan et al. Dendritic cell-based immunotherapy: a promising approach for treatment of cancer
Paglia et al. Presentation of tumor antigens: The role of dendritic cells
Jones et al. Therapeutic potential of dendritic-based vaccines
HK1161977B (en) Method to increase class i presentation of exogenous antigens by human dendritic cells
HK1049114B (en) Melanoma vaccine and methods of making and using same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120627

Termination date: 20151025

EXPY Termination of patent right or utility model